Oppenheimer raised the firm’s price target on United Therapeutics (UTHR) to $600 from $575 and keeps an Outperform rating on the shares following quarterly results. The firm says “robust” Q3 financials show the resilience of United Therapeutics’ Treprostinil franchise.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $344 from $319 at Ladenburg
- United Therapeutics price target raised to $425 from $400 at H.C. Wainwright
- United Therapeutics Reports Strong Q3 2024 Results
- United Therapeutics reports Q3 EPS $6.93, consensus $6.42
- UTHR Earnings this Week: How Will it Perform?